Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells

Oncogene

Volumn 28, Issue 38, 2009, Pages 3412-3422

  Dai, J ^a   Peng, L ^a   Fan, K ^a   Wang, H ^a   Wei, R ^c   Ji, G ^a   Cai, J ^c   Lu, B ^a   Li, B ^a   Zhang, D ^a,b   Kang, Y ^a   Tan, M ^a,b   Qian, W ^a,b   Guo, Y ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; HUVEC; Osteopontin; Signal pathway; VEGF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPONTIN; OSTEOPONTIN ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MOTILITY; CELL PROLIFERATION; CELL PROTECTION; CELL STRAIN MCF 7; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; ENDOTHELIUM CELL; FEEDBACK SYSTEM; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL SURVIVAL; CHICK EMBRYO; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOPONTIN; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 70349439129     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.189     Document Type: Article

References (33)

1. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. (1995). Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024-1028.
2. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. (1995). Inhibition of tumor growth and metastasis by an immunoneutraliz-ing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 55: 5296-5301.
3. Beraud C, Henzel WJ, Baeuerle PA. (1999). Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kB activation. Proc Natl Acad Sci USA 96: 429-434.
4. Brady H, Desai S, Gayo-Fung LM, Khammungkhune S, McKie JA et al. (2002). Effects of SP50 a novel, potent antiestrogen, on breast cancer cells and in xenograft models. Cancer Res 62: 1439-1442.
5. Cao Z, Dai J, Fan K, Wang H, Ji G, Li B et al. (2008). A novel functional motif of osteopontin for human lymphocyte migration and survival. Mol Immunol 45: 3683-3692.
6. Chakraborty G, Jain S, Kundu GC. (2008). Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68: 152-161.
7. Das R, Mahabeleshwar GH, Kundu GC. (2003). Osteopontin stimulates cell motility and nuclear factor kB- mediated secretion of urokinase type plasminogen activator through phosphatidylino-sitol 3-Kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278: 28593-28606.
8. Denhardt DT, Chambers AF. (1994). Overcoming obstacles to metastasis-defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 56: 48-51.
9. Denhardt DT. (1996). Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Crit Rev Oncog 7: 261-291.
10. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. (2001). Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055-1061.
11. Folkman J, Watson K, Ingber D, Hanahan D. (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
12. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al. (1998). Vascular endothelial growth factor regulates endothe-lial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 273: 30336-30343.
13. Hanahan D, Folkman J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
14. Jain S, Chakraborty G, Kundu GC. (2006). The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/ c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res 66: 6638-6648.
15. Javerzat S, Auguste P, Bikfalvi A. (2002). The role of fibroblast growth factors in vascular development. Trends Mol Med 8: 483-489.
16. Kane LP, Shapiro VS, Stokoe D, Weiss A. (1999). Induction of NF-kB by the Akt/PKB kinase. Curr Biol 9: 601-604.
17. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT. (2002). Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85: 728-736.
18. Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, Hermann DM. (2006). The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J 20: 1185-1187.
19. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. (1999). Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 448: 249-253.
20. L'Hote CG, Knowles MA. (2005). Cell responses to FGFR3 signaling: growth, differentiation and apoptosis. Exp Cell Res 304: 417-431.
21. Nishiyama K, Takaji K, Kataoka K, Kurihara Y, Yoshimura M, Kato A et al. (2005). Id1 gene transfer confers angiogenic property on fully differentiated endothelial cells and contributes to therapeutic angiogenesis. Circulation 112: 2840-2850.
22. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE et al. (2000). Akt/Protein kinase B upregulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275: 10761-10766.
23. Rittling SR, Chambers AF. (2004). Role of osteopontin in tumor progression. Br J Cancer 90: 1877-1881.
24. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. (1996). Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149: 293-305.
25. Shiojima I, Walsh K. (2002). Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90: 1243-1250. (Pubitemid 34787405)
26. Shijubo N, Kojima H, Nagata M, Ohchi T, Suzuki A, Abe S et al. (2003). Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech 60: 186-198.
27. Solorzano CC, Jung YD, Bucana CD et al. (2001). In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res 61: 7048-7051.
28. Standal T, Borset M, Sundan A. (2004). Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26: 179-184.
29. Toshifumi S, Ulises A, Hruska KA. (2003). PTEN regulates RANKL-and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem 278: 5001-5008.
30. Tuck AB, Chambers AF, Allan AL. (2007). Osteopontin over-expression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102: 859-868.
31. Weidner N. (1995). Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169-180.
32. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA et al. (2000). Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 18: 275:5096-275:5103.
33. Xu G, Nie H, Li N, Ni L, Xu R, Hong J et al. (2005). Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 115: 1060-1067.